TUKYSA SAFETY PROFILE
Of the most common adverse reactions in the TUKYSA arm, a majority were Grade 1 or 21
Adverse reactions in ≥10% of patients and at ≥5% higher incidence in the TUKYSA (tucatinib) arm2
|Placebo + trastuzumab
+ capecitabine (n = 197)
|TUKYSA + trastuzumab
+ capecitabine (n = 404)
|All Grades %||Grade 3 %||Grade 4 %||All Grades %||Grade 3 %||Grade 4 %|
|SKIN AND SUBCUTANEOUS TISSUE DISORDERS|
|METABOLISM AND NUTRITION DISORDERS|
|BLOOD AND LYMPHATIC SYSTEM DISORDERS|
|MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS|
|NERVOUS SYSTEM DISORDERS|
|RESPIRATORY, THORACIC, AND MEDIASTINAL DISORDERS|
- The increase in serum creatinine observed in the TUKYSA (tucatinib) arm can be attributed to the inhibition of renal tubular transport of creatinine, as opposed to impaired glomerular function, based on findings from in vitro studies2
Serious adverse reactions occurring in ≥2% of patients#
- TUKYSA (tucatinib) arm: any reaction, 26% (diarrhea, 4.0%; vomiting, 2.5%; nausea, 2.0%; abdominal pain, 2.0%; seizure, 2.0%)2
- Control arm: any reaction, 27% (diarrhea, 3.6%; vomiting, 2.5%; nausea, 1.5%; abdominal pain, 0%; seizure, 1.0%)3
- Fatal reactions: 3% in the control arm and 2% in the TUKYSA arm1,2
77% of patients in the TUKYSA arm received subsequent anticancer treatment4
*Stomatitis includes stomatitis, oropharyngeal pain, oropharyngeal discomfort, mouth ulceration, oral pain, lip ulceration, glossodynia, tongue blistering, lip blister, oral dysesthesia, tongue ulceration, and aphthous ulcer.2
†Rash includes rash maculo-papular, rash, dermatitis acneiform, erythema, rash macular, rash papular, rash pustular, rash pruritic, rash erythematous, skin exfoliation, urticaria, dermatitis allergic, palmar erythema, plantar erythema, skin toxicity, and dermatitis.2
‡Hepatotoxicity includes hyperbilirubinemia, blood bilirubin increased, bilirubin conjugated increased, alanine aminotransferase increased, transaminases increased, hepatotoxicity, aspartate aminotransferase increased, liver function test increased, liver injury, and hepatocellular injury.2
§Anemia includes anemia, hemoglobin decreased, and normocytic anemia.2
¶Peripheral neuropathy includes peripheral sensory neuropathy, neuropathy peripheral, peripheral motor neuropathy, and peripheral sensorimotor neuropathy.
#An adverse reaction is considered serious if it results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in disability, or causes a congenital anomaly/birth defect.5
PPE = palmar-plantar erythrodysesthesia.
Adverse reactions of clinical interest
- Prophylactic support to manage diarrhea was not required per HER2CLIMB protocol2
- 81% of patients who received TUKYSA experienced diarrhea, including 12% with Grade 3 and 0.5% with Grade 42
- Median time to onset (any grade) was 12 days2
- Median time to resolution was 8 days2
- Median duration of antidiarrheal use was 3 days for each 21-day repeating regimen1
- If diarrhea occurs, administer antidiarrheal treatment and perform diagnostic tests to exclude other causes, as clinically indicated; based on the severity, interrupt dose and then dose reduce or permanently discontinue TUKYSA2
- Alopecia was infrequent and mostly Grade 1 (all grades: 4.7% in the TUKYSA arm, 3.6% in the control arm; there was 1 case of Grade 2 alopecia in each arm)
Interstitial lung disease (ILD)6
- There was only 1 case of ILD in HER2CLIMB (Grade 1 pneumonitis in the TUKYSA arm), which was not considered by the investigator to be caused by the study’s agents
For information on how to manage select adverse reactions associated with TUKYSA, trastuzumab, and capecitabine, please refer to the respective Prescribing Information for each agent.
In combination with trastuzumab + capecitabine
TUKYSA is part of a well-tolerated treatment regimen2,4,6
In both treatment arms of HER2CLIMB, capecitabine was most frequently reduced, held, or discontinued due to adverse reactions6
- Adverse reactions leading to discontinuation of TUKYSA in ≥1% of patients were hepatotoxicity (1.5%) and diarrhea (1%)2
- Adverse reactions leading to dose reduction of TUKYSA in ≥2% of patients were hepatotoxicity (8%) and diarrhea (6%)2
- Frequencies of modifications and discontinuations are descriptive data that are not intended to provide conclusions about safety and should be interpreted with caution
*Reduction of the trastuzumab dose was not allowed per HER2CLIMB protocol.6
†Dose hold frequency for trastuzumab includes interruptions during infusion of trastuzumab.6
Consistent safety profile for the TUKYSA arm at 2-year follow-up4
The most common ARs (≥20%) were diarrhea, PPE, nausea, fatigue, vomiting, decreased appetite, stomatitis, headache, AST/ALT increased, anemia, bilirubin increased.
TEAEs Grade ≥3
61% (n = 245/404) in the TUKYSA arm vs 51% (n = 101/197) in the control arm
TEAEs leading to death
2% (n = 8/404) in the TUKYSA arm vs 3% (n = 6/197) in the control arm
Similar to the primary analysis, the rate of treatment discontinuation for the TUKYSA arm was 6% vs 4% in the control arm.
Follow-up safety analysis was done as part of a prespecified exploratory analysis. Results are presented as descriptive data that are not intended to provide conclusions about safety and should be interpreted with caution. Data cutoff for follow-up analysis was February 8, 2021.
Important Safety Information
Warnings and Precautions
- Diarrhea: TUKYSA can cause severe diarrhea including dehydration, hypotension, acute kidney injury, and death. In HER2CLIMB, 81% of patients who received TUKYSA experienced diarrhea, including 12% with Grade 3 and 0.5% with Grade 4. Both patients who developed Grade 4 diarrhea subsequently died, with diarrhea as a contributor to death. Median time to onset of the first episode of diarrhea was 12 days and the median time to resolution was 8 days. Diarrhea led to TUKYSA dose reductions in 6% of patients and TUKYSA discontinuation in 1% of patients. Prophylactic use of antidiarrheal treatment was not required on HER2CLIMB.
If diarrhea occurs, administer antidiarrheal treatment as clinically indicated. Perform diagnostic tests as clinically indicated to exclude other causes of diarrhea. Based on the severity of the diarrhea, interrupt dose, then dose reduce or permanently discontinue TUKYSA.
- Hepatotoxicity: TUKYSA can cause severe hepatotoxicity. In HER2CLIMB, 8% of patients who received TUKYSA had an ALT increase >5 × ULN, 6% had an AST increase >5 × ULN, and 1.5% had a bilirubin increase >3 × ULN (Grade ≥3). Hepatotoxicity led to TUKYSA dose reductions in 8% of patients and TUKYSA discontinuation in 1.5% of patients.
Monitor ALT, AST, and bilirubin prior to starting TUKYSA, every 3 weeks during treatment, and as clinically indicated. Based on the severity of hepatotoxicity, interrupt dose, then dose reduce or permanently discontinue TUKYSA.
- Embryo-Fetal Toxicity: TUKYSA can cause fetal harm. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential, and male patients with female partners of reproductive potential, to use effective contraception during TUKYSA treatment and for at least 1 week after the last dose.
Serious adverse reactions occurred in 26% of patients who received TUKYSA; those occurring in ≥2% of patients were diarrhea (4%), vomiting (2.5%), nausea (2%), abdominal pain (2%), and seizure (2%). Fatal adverse reactions occurred in 2% of patients who received TUKYSA including sudden death, sepsis, dehydration, and cardiogenic shock.
Adverse reactions led to treatment discontinuation in 6% of patients who received TUKYSA; those occurring in ≥1% of patients were hepatotoxicity (1.5%) and diarrhea (1%). Adverse reactions led to dose reduction in 21% of patients who received TUKYSA; those occurring in ≥2% of patients were hepatotoxicity (8%) and diarrhea (6%).
The most common adverse reactions in patients who received TUKYSA (≥20%) were diarrhea, palmar-plantar erythrodysesthesia, nausea, fatigue, hepatotoxicity, vomiting, stomatitis, decreased appetite, abdominal pain, headache, anemia, and rash.
In HER2CLIMB, Grade ≥3 laboratory abnormalities reported in ≥5% of patients who received TUKYSA were decreased phosphate, increased ALT, decreased potassium, and increased AST.
The mean increase in serum creatinine was 32% within the first 21 days of treatment with TUKYSA. The serum creatinine increases persisted throughout treatment and were reversible upon treatment completion. Consider alternative markers of renal function if persistent elevations in serum creatinine are observed.
- Strong CYP3A/Moderate CYP2C8 Inducers: Concomitant use may decrease TUKYSA activity. Avoid concomitant use of TUKYSA.
- Strong or Moderate CYP2C8 Inhibitors: Concomitant use of TUKYSA with a strong CYP2C8 inhibitor may increase the risk of TUKYSA toxicity; avoid concomitant use. Increase monitoring for TUKYSA toxicity with moderate CYP2C8 inhibitors.
- CYP3A Substrates: Concomitant use may increase the toxicity associated with a CYP3A substrate. Avoid concomitant use of TUKYSA where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, decrease the CYP3A substrate dosage.
- P-gp Substrates: Concomitant use may increase the toxicity associated with a P-gp substrate. Consider reducing the dosage of P-gp substrates where minimal concentration changes may lead to serious or life-threatening toxicity.
Use in Specific Populations
- Lactation: Advise women not to breastfeed while taking TUKYSA and for at least 1 week after the last dose.
- Renal Impairment: Use of TUKYSA in combination with capecitabine and trastuzumab is not recommended in patients with severe renal impairment (CLcr < 30 mL/min), because capecitabine is contraindicated in patients with severe renal impairment.
- Hepatic Impairment: Reduce the dose of TUKYSA for patients with severe (Child-Pugh C) hepatic impairment.
TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
Please see full Prescribing Information.
1. Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;382(7):597-609. 2. TUKYSA [Prescribing Information]. Bothell, WA: Seagen Inc. February 2022. 3. Data on file. Seagen Inc. 4. Curigliano G, Mueller V, Borges V, et al. Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB). Poster presented at: American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. 5. Food and Drug Administration. What is a serious adverse event? Updated February 1, 2016. Accessed April 26, 2022. https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event 6. Okines A, Paplomata E, Wahl T, et al. Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB). Poster presented at: American Society of Clinical Oncology Annual Meeting; May 29-31, 2020.